a novel platform for cancer therapy using a exracellular vesicles
TRANSCRIPT
![Page 1: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/1.jpg)
Guide:Dr. K. N. Gujar
Co-Guide: Dr. M. S. Gambhire
Presented By:Aniket A. Vaidhya M. Pharm, Sem.- II
(Pharmaceutics) Roll.no:522
Sinhgad College of Pharmacy Vadgaon (Bk), Pune (41)
Seminar on
A Novel Platform For Cancer Therapy Using Extracellular Vesicles
1
(2016)12/ 04/2016
![Page 2: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/2.jpg)
2 Extracellular Vesicles
Cell-Derived Vesicles Both Eukaryotic and Prokaryotic cells release vesicles. Evs are spherical particles enclosed by a phospholipid
bilayer. The diameter of vesicles typically ranges from 30 nm to 1
µm. Most vesicles have specialized functions and play a key
role in, intercellular signaling, waste management, and coagulation.
Nowadays Vesicles can potentially be used for therapy, prognosis, and biomarkers for health and disease.
AN
IKE
T VA
IDYA
Ref.: Andaloussi Samir EL .Extracellular vesicles: biology and emerging therapeutic opportunities, Nature Reviews Drug Discovery .2015: Vol 12.347-358.
![Page 3: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/3.jpg)
3
Contain several types of function molecules, such as proteins, mRNAs, and miRNAs.
Emerged as potential tools for a Drug Delivery system that can target organs or cells.
Have a function of Organ Tropism . They are Laturally occurring from cells. Have a Low side effect. Delivered drugs to specific organ.
AN
IKE
T VA
IDYA
Ref.: Tominaga Naoomi .A novel platform for cancer therapy using extracellular vesicles ,Advanced Drug Delivery Reviews.2015:Vol. 10.1-6.
![Page 4: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/4.jpg)
4 History
The discovery of cell-derived vesicles 1940, when preliminary studies were performed, addressing the
“biological significance of the thrombo plastin protein of blood” (Chargaff and West, 1946).
that cell-free plasma contains a subcellular factor that promotes clotting of blood (Chargaff and West, 1946).
More than 20 years later, in 1967, this subcellular fraction was identified by electron microscopy and was shown to consist of small vesicles, originating from platelets and termed platelet dust” (Wolf, 1967).
AN
IKE
T VA
IDYA
Ref.: Pol Edwin vander .“Classification, Functions, and Clinical Relevance of Extracellular Vesicles” The American Society for Pharmacology and Experimental Therapeuics . 2012: Vol. 64, No. 3 pg no. 676–705.
![Page 5: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/5.jpg)
5
These vesicles diameter between 20 and 50 nm and density of 1.020 to 1.025 g/ml (Wolf, 1967). One decade later, fetal calf serum was also shown to
contain “numerous microvesicles” ranging in diameter from 30 to 60 nm (Dalton, 1975).
the term “Exosomes” was introduced when vesicles were isolated from conditioned culture medium of sheep reticulocytes. (John stone , 1987).
AN
IKE
T VA
IDYA
Cont..
Ref.: Pol Edwin vander .“Classification, Functions, and Clinical Relevance of Extracellular Vesicles” The American Society for Pharmacology and Experimental Therapeuics . 2012: Vol. 64, No. 3 pg no. 676–705.
![Page 6: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/6.jpg)
6Different types of Evs A
NIK
ET
VAID
YA
Microvesicles
Apoptotic bodies
Exosome
Ref.: Tominaga Naoomi .A novel platform for cancer therapy using extracellular vesicles ,Advanced Drug Delivery Reviews.2015:Vol. 10.1-6.
![Page 7: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/7.jpg)
7 Microvesicles (MVs)
MVs are structures surrounded by a phospholipid bilayer. ( 100–1,000 nm in diameter )
Their size range overlaps that of bacteria. They are formed by regulated release by budding/ blebbing of the
plasma membrane. They have been characterized as products of Platelets, Red blood cells
and Endothelial cells. Isolation and analytical methods include Differential Centrifugation ,
Flow Cytometry (FC) and Capture-based assays.
AN
IKE
T VA
IDYA
Ref.: Zaborowski Mikołaj P. “Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study,”BioScience Advance Access, 2015. Vol.20.1-15.
![Page 8: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/8.jpg)
8 Apoptotic bodies
The term ‘‘apoptotic body’’ was coined by Kerr in 1972 . Apoptotic bodies are 1–5 µm in diameter (approximately
the size range of platelets) Apoptotic bodies are released as blebs of cells undergoing
apoptosis. key functions of apoptotic bodies are horizontal transfer of
oncogenes , horizontal transfer of DNA. Due to Uptake of apoptotic bodies it lead to immuno
suppression .
AN
IKE
T VA
IDYA
Ref.: Zaborowski Mikołaj P. “Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study,”BioScience Advance Access, 2015. Vol.20.1-15.
![Page 9: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/9.jpg)
9 Exosomes
First described by Trams in 1983 They are vesicles surrounded by a phospholipid bilayer
(approximately 50–100 nm in diameter), their size range roughly overlaps that of the viruses.
They are released by exocytosis of multivesicular bodies. Exosomes have been predominantly characterized in the
case of immune cells (dendritic cells, T cell, B cells, macrophages) and tumors.
AN
IKE
T VA
IDYA
Ref.: Zaborowski Mikołaj P. “Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study,”BioScience Advance Access, 2015. Vol.20.1-15.
![Page 10: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/10.jpg)
10
Key mechanisms by which exosomes may exert their biological functions on cells include
(1) Direct contact between surface molecules of vesicles and cells,
(2) Endocytosis of vesicles,
(3) Vesicle-cell membrane fusion . Exosomes may horizontally transfer mRNA and miRNA .
AN
IKE
T VA
IDYA
Cont..
Ref.: Zaborowski Mikołaj P. “Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study,”BioScience Advance Access, 2015. Vol.20.1-15.
![Page 11: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/11.jpg)
11 Size Ranges of Membrane Vesicles
AN
IKE
T VA
IDYA
Ref.: Gyorgy Bence .“Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles”, Cellular and Molecular Life Sciences.Springer.2011: 68:2667–2688.
![Page 12: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/12.jpg)
12Schematic Representation of EVS
AN
IKE
T VA
IDYA
Ref.: Gyorgy Bence .“Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles”, Cellular and Molecular Life Sciences.Springer.2011: 68:2667–2688.
![Page 13: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/13.jpg)
13A
NIK
ET
VAID
YA
Ref.: Zaborowski Mikołaj P. “Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study,”BioScience Advance Access, 2015. Vol.20.1-15.
![Page 14: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/14.jpg)
14 Characteristics of Different Types of EVs
Ref.: Vader Pieter .“Extracellular vesicles: emerging targets for cancer therapy”, Trends in Molecular Medicine.2014: Vol. 20. 385-393.
![Page 15: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/15.jpg)
15 Exosomes
Natural Nanoparticles for use as Drug Delivery vesicles. Exosomes are smallest extracellular vesicles. Size=30–100 nm originates from late endosomes. Formed in multivesicular bodies inside the cells. Released in the extracellular medium by a broad array of
cells.
AN
IKE
T VA
IDYA
Ref.: Zaborowski Mikołaj P. “Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study,”BioScience Advance Access, 2015. Vol.20.1-15.
First identified in sheep red blood cell ( 1983) -Believed to be a mechanism for the exchange of proteins between cells.
![Page 16: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/16.jpg)
16 Composition
Exosomes are composed of a wide range of contents including:
Proteins ( integrins, selectins, Rab proteins, tetraspanins like CD9, CD81, CD63 etc)
Lipids (e.g, steroids, sphingolipids, glycerophospholipids) Nucleic acids (mRNA, miRNA, sRNA, DNA) Growth receptors Soluble factors
AN
IKE
T VA
IDYA
Ref.: Zaborowski Mikołaj P. “Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study,”BioScience Advance Access, 2015. Vol.20.1-15.
![Page 17: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/17.jpg)
17
Ref.: Gupta Archana .“Exosome as a Mediators of Neuroinflamation,” Journal Of Neuroinflamation,2014.Vol.15.11-68.
Cont..A
NIK
ET
VAID
YA
![Page 18: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/18.jpg)
18 Functions
Different biological functions both in normal and pathophysiological conditions.
Elimination of un-necessary proteins & molecules from cell and blood coagulation.
Exchange of materials between cells, intercellular communication.
Propagation of pathogens, immune responses (inhibitory and regulatory).
AN
IKE
T VA
IDYA
Ref.: Zaborowski Mikołaj P. “Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study,”BioScience Advance Access, 2015. Vol.20.1-15.
![Page 19: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/19.jpg)
19 Biogenesis and Release of Exosome A
NIK
ET
VAID
YA
Ref.: Raposo Graça. “Extracellular vesicles: Exosomes, microvesicles, and friends”The Journal Of Cell Biology, 2013. Vol. 200.373-383.
![Page 20: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/20.jpg)
20 Biogenesis and Release of Exosome
Released by B‐cells, dendritic cells (DCs), T‐cells, epithelial cells, platelets
present in physiological fluids serum, urine, breast milk, cerebrospinal fluid, saliva
AN
IKE
T VA
IDYA
Ref.: Zaborowski Mikołaj P. “Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study,”BioScience Advance Access, 2015. Vol.20.1-15.
![Page 21: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/21.jpg)
21 Synthesis and Secretion:
The process of exosome biogenesis is divided into four stages Initiation Endocytosis Multivesicular bodies (MVBs) formation and Exosome secretion
AN
IKE
T VA
IDYA
Ref.: Zaborowski Mikołaj P. “Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study,”BioScience Advance Access, 2015. Vol.20.1-15.
![Page 22: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/22.jpg)
22 Roles of exosomes in cancer
AN
IKE
T VA
IDYA
Ref.: Zhang XU.“Exosomes in cancer: small particle”, big player Journal of Hematology & Oncology . 2015:8:83.
![Page 23: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/23.jpg)
23 CASE STUDY 1
(i) Prepare and characterize a new formulation of exosomes loaded with PTX (exoPTX), (ii) Assess the feasibility using exoPTX for MDR-related anticancer therapy.
Objective
![Page 24: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/24.jpg)
24A
NIK
ET
VAID
YA
Graphical Abstract
![Page 25: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/25.jpg)
25
Materials
Paclitaxel (PTX) and Doxorubicin (DOX) , Lipophilic fluorescent dyes, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindo-carbocyanine
perchlorate (DIL), Rhodamine 123 (R123), Cell culture medium and fetal bovine serum (FBS), ExoQuick-TC™ Exosome Precipitation Solution.
AN
IKE
T VA
IDYA
![Page 26: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/26.jpg)
26
Exosome harvested from the conditioned media of RAW 264.7 cells cultured in exosome depleted media using the ExoQuick-TC kit
Exosome Characterization Nanoparticle tracking analysis Dynamic light scattering Atomic force microscopy Western blot analysis
AN
IKE
T VA
IDYA
Harvesting of Exosome
![Page 27: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/27.jpg)
27 Drug Loading into Exosomes
METHOD
Incubation at room temperature (RT)
Electroporation
Sonication
AN
IKE
T VA
IDYA
![Page 28: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/28.jpg)
28Incubation method
Purified exosomes were first mixed with PTX in 1 mL PBS.
Admixture was incubated at 37°C for 1 hour with shaking.
AN
IKE
T VA
IDYA
![Page 29: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/29.jpg)
29 Eelectroporation method
Exosomes were mixed with PTX
Added to a chilled 4 mm electroporation cuvette.
The mixture was then electroporated using an Eppendorf Eporator at 1000 kV for 5 ms,
Then incubated at 37°C for 30 min to allow for recovery of the exosomal membrane.
AN
IKE
T VA
IDYA
![Page 30: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/30.jpg)
30 Sonication Method
PTX-exosome mixture was sonicated using a Model 505 Sonic Dismembrator .(settings: 20% amplitude, 6 cycles of 30 s on/off for three minutes with a two minute cooling period between each cycle.)
After sonication, exoPTX solution were incubated at 37°C for 60 min to allow for recovery of the exosomal membrane.
Excess free drug was separated from exoPTX by size exclusion chromatography.
AN
IKE
T VA
IDYA
![Page 31: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/31.jpg)
31 Characterization
•Accumulation of exosomes and exosome-incorporated PTX in cancer cells
•In vitro Cytotoxicity Assay
•Biodistribution of Exosomes in Mice with Pulmonary Metastases
•Therapeutic Efficacy of exoPTX against Pulmonary Metastases
AN
IKE
T VA
IDYA
![Page 32: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/32.jpg)
32 Characterization of PTX exosomal formulations
RESULTSA
NIK
ET
VAID
YA
A) The size of exoPTX was measured by NTA and DLS
B) The exosome protein content was confirmed by western blot
D) The morphology of drug-loaded exosomes was examined by AFM
![Page 33: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/33.jpg)
33 A profound accumulation of exosomes in 3LL-M27 cells in vitro
3LL-M27 cells were incubated with fluorescently-labeled (red) exosomes, or liposomes, NPs for various times and the amount of accumulated nanocarriers was examined by confocal microscopy (A), and spectrophotometry (B). Bar: 10 μm.
AN
IKE
T VA
IDYA
![Page 34: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/34.jpg)
34 Effect of Pgp inhibition on Dox in MDR and sensitive cancer cells
The accumulation of free Dox or exoDox in MDCK MDR1 and MDCK WT cells was studied in celllysates. The Dox incorporation into exosomes significantly increased accumulation in sensitiveand resistant cells, while no effect of verapamil on exoDOX accumulation was found in both celllines.
AN
IKE
T VA
IDYA
![Page 35: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/35.jpg)
35
The inhibition of metastases growth in mouse lungs upon exoPTX treatment.
C57Bl/6 mice were i.v. injected with 8FlmC-FLuc-3LL-M27 (red) cells to establish pulmonarymetastases. 48 hour later mice were treated with exoPTX, or Taxol, or saline, or empty sonicatedexosomes as a control, and the treatment was repeated every other day, totally seven times.
AN
IKE
T VA
IDYA
![Page 36: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/36.jpg)
36Mechanistic studies of exoPTX cytotoxic effects
RRI for exoPTX in MDCK MDR1 and MDCK WT was 53.33 and 18.38, respectively. In contrast, RRI for Taxol in both resistant and sensitive cancer cells . Noteworthy, empty sonicated exosomes did not show any cytotoxicity in all studied cell lines. Thus, the increase in PTX cytotoxicity afforded by exoPTX was greater in Pgp-overexpressing cells than their sensitive counterparts.
AN
IKE
T VA
IDYA
![Page 37: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/37.jpg)
37 Conclusion
Exosome carriers can provide advantages of cell based drug delivery.
In this case study they utilise three methods in that mild sonication of exosomes in the presence of PTX provided the greatest loading capacity.
Also long term stability. Incorporation of PTX into exosomes may not only
increase its solubility, but also allow for overcoming of Pgp-mediated drug efflux.
AN
IKE
T VA
IDYA
![Page 38: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/38.jpg)
38 CASE STUDY 2
![Page 39: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/39.jpg)
39 Method
The pEGFP-C1-RVG-Lamp2b expressing vector . Reengineered the vector by replacing the RVG fragment
with iRGD (pEGFP-C1-iRGD-Lamp2b)
AN
IKE
T VA
IDYA
![Page 40: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/40.jpg)
40 Conclusion
Shown that iRGD-targeted exosomes, a simple and natural nanoscale drug delivery platform
Are highly efficient in targeting chemotherapeutic drug to tumors in mice,
Thus they represent a promising approach for cancer therapy in humans.
AN
IKE
T VA
IDYA
![Page 41: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/41.jpg)
41 Reference1) Tominaga Naoomi .A novel platform for cancer therapy using extracellular
vesicles ,Advanced Drug Delivery Reviews.2015:Vol. 10.1-6.
2) Andaloussi Samir EL .Extracellular vesicles: biology and emerging therapeutic opportunities, Nature Reviews Drug Discovery .2015: Vol 12.347-358.
3) Johnny C. Akers .Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies, J Neurooncol , Springer .2013:Vol.113,1-11.
4) Pol Edwin vander .“Classification, Functions, and Clinical Relevance of Extracellular Vesicles” The American Society for Pharmacology and Experimental Therapeuics . 2012: Vol. 64, No. 3 pg no. 676–705.
5) Gyorgy Bence .“Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles”, Cellular and Molecular Life Sciences.Springer.2011: 68:2667–2688.
AN
IKE
T VA
IDYA
![Page 42: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/42.jpg)
426) Mar Gudbergsson Johann. “Systematic review of factors influencing
extracellular vesicle yield from cell cultures” Cytotechnolog, Springer.2013:Vol. 10.1007-1016.
7) Vader Pieter .“Extracellular vesicles: emerging targets for cancer therapy”, Trends in Molecular Medicine.2014: Vol. 20. 385-393.
8) Raposo Graça. “Extracellular vesicles: Exosomes, microvesicles, and friends”The Journal Of Cell Biology, 2013. Vol. 200.373-383.
9) Zhang XU.“Exosomes in cancer: small particle”, big player Journal of Hematology & Oncology . 2015:8:83.
10) Kate M. Candelario .The role of EVS in the Progression of cancer, Trends in molecular medicine 2015:Vol.20. 368-374.
AN
IKE
T VA
IDYA
Cont..
![Page 43: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/43.jpg)
43
11) Myung soo kim. “Development of Exosome-encapsulated paclitaxel to Overcome MDR in cancer cells”. Journal of Nanomedicine.2015.10.012.
12) Yanhua Tian. “A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy” Journal of Biomaterials . 2014:35 .383-2390.
13) Zaborowski Mikołaj P. “Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study,”BioScience Advance Access, 2015. Vol.20.1-15.
14) Gupta Archana .“Exosome as a Mediators of Neuroinflamation,” Journal Of Neuroinflamation,2014.Vol.15.11-68.
Cont..
![Page 44: A Novel Platform for cancer Therapy using a Exracellular vesicles](https://reader035.vdocuments.site/reader035/viewer/2022081521/587d390a1a28ab2a448b67cf/html5/thumbnails/44.jpg)
44